Drugs / LY3876602
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06007638 | Aug 2023 → Sep 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3876602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06007638 ↗ |
| Route | Intravenous | “Single ascending doses of LY3876602 administered intravenously (IV).” NCT06007638 ↗ |